Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • AKTS: Two Customers Signed and More in the Works Zacks Small Cap Research - 11 hours ago

    Akoustis (AKTS) is continuing to make progress with new customers in the mobile phone space in China including both RF front-end makers and mobile phone OEMs. The front-end makers are primarily using SAW filters and looking for BAW solutions for their customers. A new market is developing that Akoustis is eager to pu …

  • CANF: Ready to Start Two Phase III Trials in 2017 Zacks Small Cap Research - 11 hours ago

    On Feb. 8, 2017, Can-Fite (CANF) announced through a news release that the Company is ready to commence patient enrollment in the 2Q17 in its global Phase III trial of its lead drug candidate Piclidenoson (CF101) as a first line treatment for rheumatoid arthritis (RA). The EMA suggested Piclidenoson should be developed …

  • SNGX: Potential Expansion of Synthetic Hypericin into Psoriasis Zacks Small Cap Research - Wed, Feb 22, 2017 10:00 AM EST

    Earlier this morning (Feb. 22, 2017), Soligenix (SNGX) announced that its proprietary formulation of synthetic hypericin has been granted a European patent for the treatment of psoriasis. The issued patent, EP 2571507, Formulations and methods of treatment of skin conditions, complements the method of treatment claims …

  • VIVE: Guiding for ~100%+ Revenue Growth in 2017 Zacks Small Cap Research - Tue, Feb 21, 2017 2:00 PM EST

    Viveve (VIVE) reported financial results for the fourth quarter ending December 31st and provided a business update.  Management also provided initial 2017 revenue guidance of $14M - $16M, which implies growth of 96% - 124%, and also noted that they expect strong improvement in gross margin. Relative to Q4, it marked the …

  • LMD.V: Apteryx Looks To Be Great Fit for LED Medical Zacks Small Cap Research - Tue, Feb 21, 2017 12:00 PM EST

    LED mentioned little after that regarding the potential acquisition until this January when they announced their intent to acquire Apteryx, Inc., an Ohio-based company which develops and sells software primarily for the dental industry.  The deal closed earlier this week. Apteryx looks like it could be a great fit for …

  • The Appointment of New CEO is Supposed to Bring COT.V to a New Level Zacks Small Cap Research - Fri, Feb 17, 2017 10:00 AM EST

    In early December 2016, Critical Outcome Technologies (COT.V) (COTQF) appointed Alison Silva as the Company’s new Chief Executive Officer (CEO) effective January 1, 2017. Ms. Silva served before the appointment on the Board of Directors and as President. Alison has worked with COT.V in various roles since 2013, during …

  • ONGENTYS® is a once-daily, highly-selective catechol-O-methyltransferase (COMT) inhibitor that was approved in June 2016 by the European Medicines Agency (EMA) as an adjunct therapy along with levodopa/DOPA decarboxylase inhibitors for adults with Parkinson’s disease. Parkinson’s disease (PD) is a slowly progressing neurological …

  • 3 Companies Looking to Capitalize on Orphan Designation with Multiple Catalyst Zacks Small Cap Research - Thu, Feb 16, 2017 9:00 AM EST

    Orphan Designation Provides Incentives, Confidence to BioVie, Inc. Orphan Drug designation can be a substantial benefit to small biopharmaceutical companies. When the U.S. FDA designates a drug for an orphan indication, it comes with certain advantages that save the developing company time and money, as well as protects …

  • VKTX: Successful Preclinical Data for VK2809 in Glycogen Storage Disease 1a Zacks Small Cap Research - Wed, Feb 15, 2017 1:00 PM EST

    Initial results from the study showed that treatment with VK2809 led to statistically significant reductions in key metabolic markers of GSD 1a, including a reduction in mean liver triglyceride content of more than 60%, a reduction in average liver weight of more than 30%, and a reduction in average liver weight as a percentage …

  • DMA.V: DM199 and Diabetic Kidney Disease (DKD) Zacks Small Cap Research - Wed, Feb 15, 2017 12:00 PM EST

    In addition to AIS, DiaMedica (DMA.V) (DMCAF) is also developing DM199 for the treatment of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) or Diabetic nephropathy (DN) is one of the most common complications of late stage diabetes. DKD is a form of chronic kidney disease (CKD) characterized by a gradual …

  • DRRX: Update on DUR-928 Development Program Zacks Small Cap Research - Wed, Feb 15, 2017 12:00 PM EST

    By Grant Zeng, CFA NASDAQ:DRRX Among Durect’s (NASDAQ:DRRX) multiple candidates, DUR-928 may be the most promising one in our view because this compound has the potential to target multiple indications ...

  • DiaMedica: A Key Player in the area of AIS and DKD Zacks Small Cap Research - Wed, Feb 15, 2017 10:00 AM EST

    DiaMedica Therapeutics Inc. (DMA.V) (DMCAF) is a clinical stage biopharmaceutical company focused on the development and commercialization of DM199 for the treatment of acute ischemic stroke (AIS) and diabetic kidney disease (DKD). The company’s lead drug candidate DM199 is a recombinant human tissue kallikrein (KLK1). …

  • AEMD: FDA Discussions Regarding U.S. Clearance Pathway Zacks Small Cap Research - Wed, Feb 15, 2017 9:00 AM EST

    Aethlon (AEMD) reported financial results for their fiscal third quarter 2017 (ending December 2016) and provided an operational update.  There were no meaningful surprises in the financial results relative to our expectations with the top-line ($0 A vs. $8k E), operating expenses ($1.2M A vs. $1.3M E), net loss ($1.2M …

  • GOVX: Multiple Progress Made in the Last Two Months Zacks Small Cap Research - Tue, Feb 14, 2017 4:00 PM EST

    By Grant Zeng, CFA OTC:GOVX New CSO Appointed On December 14, 2016, GeoVax (OTC:GOVX) announced that the company has promoted Farshad Guirakhoo , PhD, to the role of Chief Scientific Officer (CSO), effective ...

  • INUV: The Purchase of NetSeer Should Return Inuvo to Growth Zacks Small Cap Research - Tue, Feb 14, 2017 3:00 PM EST

    On February 7th the company (INUV) announced the purchase of most of the assets of NetSeer, for 3.529 million shares of stock (or $5.8 million) and assumed $4.2 million in liabilities related to the business, comprised of debt to a bank, debt to a lender, trade payables, and severance. The acquisition is expected to add …

  • PAT.V: Can Patriot One Technologies Disrupt the Weapons Scanning Market? Zacks Small Cap Research - Tue, Feb 14, 2017 10:30 AM EST

    Governments and enterprises are constantly looking for improved, cost-effective ways to keep people safe, which includes the use of scanners and metal detectors to screen for weapons in many public locations. A new technology for this type of screening is being commercialized by Patriot One Technologies (PAT.V) (PTOTF), …

  • TSEM: Q4 Results: TowerJazz Plays Out the Year With Record Revenues and Profits Zacks Small Cap Research - Tue, Feb 14, 2017 9:00 AM EST

    The company gave midpoint guidance of $330 million in revenue for Q1 2017, pointing to revenue growth of 19%. Gross margin for the quarter was 25.8% versus 25.3% last year and 24.9% in Q3 2016. While revenues grew 34%, operating income grew 61% to 16% of sales.

  • ESDI (ESDI) to move its operations to improve manufacturing efficiencies and reduce manufacturing costs. Eastside Distilling is in the process of negotiating a sublease in a new manufacturing facility.

  • APDN: An DNA solution for product authentication Zacks Small Cap Research - Mon, Feb 13, 2017 2:00 PM EST

    Total revenue for the fiscal first quarter was $0.9 million, compared with $1.32 million reported in the first quarter of fiscal 2016, a decrease of 32%. Total revenue for 1Q17 also decreased 45% from the $1.64 million reported in the fourth fiscal quarter ended September 30, 2016.

  • S&W Seed (SANW) announced its second fiscal quarter financials on February 09, 2017 followed by a conference call. Gross margins improved, as expected, from 16.7% to 21.6% due to improved cost control and a better product mix. S&W Seed announced it had signed a stevia R&D collaboration deal with a major consumer products …

  • CBMX:Expect Record Revenue, Profit in 2017 On Strong Fundamentals Zacks Small Cap Research - Fri, Feb 10, 2017 9:00 AM EST

    Through the first nine months of 2016 CombiMatrix’s (CBMX) revenue is up 26%, gross margin is 800 basis points wider, operating loss is 28% lower and EBITDA loss is improved by almost 38% as compared to the same period in 2015.  As we have recently noted, we characterize the improved financial performance as ‘high quality’ …

  • AMERCO (UHAL) reported is financials for the 3Q17 on February 8, 2017, followed by a conference call the next day. All of the operating expenses except depreciation were close to our estimates. Transactions continue to increase on a year/year basis and dollar value per transaction was about the same as in 2Q17, which …

  • SBOT: Q1 Light On Revenue But Clinical Trial Progression Suggests Growth Ahead Zacks Small Cap Research - Thu, Feb 9, 2017 8:15 AM EST

    Q1 revenue was $142k (vs. $308k estimate), all of which relates to product sales.  As a reminder, as a result of the conclusion of services related to a two-year contract, SBOT has not booked any contract services-related revenue since fiscal Q1 2016. Q1 net loss and EPS were $1.5M and ($0.15) vs. our $1.8M and ($0.18) …

  • Q1 Light On Revenue But Clinical Trial Progression Suggests Growth Ahead Zacks Small Cap Research - Thu, Feb 9, 2017 8:15 AM EST

    Q1 revenue was $142k (vs. $308k estimate), all of which relates to product sales.  As a reminder, as a result of the conclusion of services related to a two-year contract, SBOT has not booked any contract services-related revenue since fiscal Q1 2016. Q1 net loss and EPS were $1.5M and ($0.15) vs. our $1.8M and ($0.18) …

  • TENX: Tenax Reports LEVO-CTS Topline Results Zacks Small Cap Research - Wed, Feb 8, 2017 4:50 PM EST

    By  John Vandermosten, CFA NASDAQ:TENX On January 31, 2017, Tenax Therapeutics, Inc. (NASDAQ:TENX) announced topline results from its Phase 3 LEVO-CTS trial in cardiac surgery.  The trial’s primary endpoints ...

  • ICAD: Certain Catalysts Expected to Return ICAD to Positive Revenue Growth in 2017 Zacks Small Cap Research - Wed, Feb 8, 2017 4:15 PM EST

    Certain Catalysts Expected to Return ICAD (ICAD) to Positive Revenue Growth in 20172016 has been a disappointing year in terms of revenue.  Therapy revenue through the first nine months of the year is down 66%, largely as a result of the unfavorable change to reimbursement of non-melanoma skin cancer.  Detection revenue …

  • ESDI: Expanding marketing presence in Oregon with two more tasting rooms Zacks Small Cap Research - Wed, Feb 8, 2017 2:30 PM EST

    ESDI to double number of tasting rooms which will lead to an increase in profits. The company has announced that it will double the number of tasting rooms, from two to four, in Oregon. Tasting rooms are excellent outlets for seasonal spirits and for local varieties that are produced in small quantities.

  • Revenue was slightly below our estimate but gross margins increased again and operating expenses were below our estimates (we exclude restructuring and impairment charges from operating results and including them in other income). Operating income and pretax income were above our forecasts. The strong US dollar versus …

  • By Steven Ralston, CFA TSX:GOM.V OTC:GDMRF Golden Dawn Minerals (TSX:GOM.V) (OTC:GDMRF) recently filed a NI 43-101-complaint Technical Report on Kettle River land package. Also, earlier in January, the ...

  • By Steven Ralston, CFA TSX:GOM.V OTC:GDMRF Golden Dawn Minerals (TSX:GOM.V) (OTC:GDMRF) recently filed a NI 43-101-complaint Technical Report on Kettle River land package. Also, earlier in January, the ...

  • ESDI: Bolstering marketing with social media. Zacks Small Cap Research - Mon, Feb 6, 2017 10:00 AM EST

    By Ian Gilson, PhD,CFA OTC:ESDI Eastside Distilling has hired L&A Social Media to expand its marketing efforts through social media with initial efforts on increasing its exposure to Portland Potato Vodka.  ...

  • EYEG: Positive OBG Clinical Data, Larger Study Already Planned Zacks Small Cap Research - Fri, Feb 3, 2017 2:30 PM EST

    Earlier this week (Jan 30th) EyeGate (EYEG) announced encouraging top-line results of its human pilot study of its Ocular Bandage Gel (OBG).  While the study was small, results indicate that OBG may be associated with faster corneal healing following eye surgery as compared to standard of care.  We view this as meaningfully …

  • PBSV: Fiscal Q4 2016 Results Zacks Small Cap Research - Fri, Feb 3, 2017 11:30 AM EST

    Puerto Rico, which accounts for ~75% of total sales, fell 17%, U.S. (~8% of total sales) fell 46% and Europe (~4% of total sales) fell 25%.  The sole revenue-related highlight was the lab segment, which accounts for approximately 12% of total sales and posted 22% yoy growth in 2016. The major contributor to overall top-line …

  • VBI Vaccines Inc. (VBIV) is a commercial stage biopharmaceutical company developing treatments for infectious disease and immuno-oncology. The company produces a third-generation hepatitis B vaccine, Sci-B-Vac™, which is currently marketed in 15 countries, including Israel where it has 50% market share. The pipeline consists …

  • The company has reported that it has added 45 new varieties to its alfalfa portfolio, none of which have been marketed by S&W Seed (SANW). Salt tolerance is important in many parts of the world, such as parts of the Imperial Valley in S. California, where the soil has been contaminated by many years of excessive fertilization …

  • SNWV: Record Revenue As International Strategy Builds Momentum Zacks Small Cap Research - Wed, Feb 1, 2017 10:00 AM EST

    In December SANUWAVE (SNWV) provided a fourth quarter update which included an expectation that Q4 revenue would come in at a relatively strong $450k - $650k, bolstered by a more than doubling of units shipped during 2016 as compared to the prior year.  Then last week (1/26) the company narrowed that Q4 revenue guidance …

  • SCLP: A Vanguard in Cancer Vaccines: 2 Platforms, 3 Products, 5 Indications Zacks Small Cap Research - Tue, Jan 31, 2017 12:00 PM EST

    Scancell Holdings Plc. (SCLP.L) is a UK-based, cancer-focused, biotechnology company developing three vaccine products for skin, lung, breast and ovarian and osteosarcoma.  The company has shown exciting promise in its lead immunotherapy candidate, SCIB1, in the treatment of melanoma, which it expects to be particularly …

  • VIVE: Major Milestone Crossed With U.S. Entry. Reiterate $11 Target Zacks Small Cap Research - Mon, Jan 30, 2017 2:00 PM EST

    Viveve (VIVE) recently crossed what we characterize as a major milestone with the entry of the Viveve System into the U.S. market and the announcement last week that they have begun deployment of their initial domestic sales force.  Management laid out their initial U.S. commercialization plans on the Q3 call (November), …

  • Great Lakes Graphite (GLK.V) Joins the Graphite Supply Chain Zacks Small Cap Research - Mon, Jan 30, 2017 11:00 AM EST

    Headquartered in Toronto, Great Lakes Graphite Inc. (GLK.V) (GLKIF) is an industrial minerals company that is currently focused on marketing and supplying value-added graphite products to customers in North America. In 2016, the company joined the graphite supply chain by fulfilling several orders for synthetic graphite, …

  • AEMD: New CTE Study Largest in Ex-NFL Players Zacks Small Cap Research - Fri, Jan 27, 2017 11:00 AM EST

    Following conclusion of the DARPA DLT sepsis-related program, Aethlon (AEMD) wasted little time in allocating its focus on other high-priority programs, including further validation of Hemopurifier in the capture of certain viruses and pathogens  - progress which could lead towards eventually utility of the device in a …

  • O2Micro (OIIM) Reports High End of Expected Q4 Revenue Range Zacks Small Cap Research - Thu, Jan 26, 2017 4:00 PM EST

    Since our last report earlier this month, when O2Micro (OIIM) raised guidance for this just reported Q4, its stock has moved up 43%. Were we to use the average enterprise value to trailing twelve-month sales of 5.5 times and apply it to OIIM’s Q4 $64 million revenue run rate, we would calculate an enterprise value of $352 …

  • BMRA: Analysis of IBS Drugs Indicates Unmet Need for Alternative Therapies Zacks Small Cap Research - Thu, Jan 26, 2017 10:30 AM EST

    Biomerica (BMRA) reported financial results for their fiscal second quarter ending November 30.  Revenue, for the second straight quarter, surprised on the upside by about 12% relative to our estimate with the majority of the beat in both periods related to stronger than anticipated sales in Asia.  Similarly, it wasn’t …

  • YOSPRALA™ is composed of a delayed-release aspirin (either 81 mg or 325 mg) and an immediate-release omeprazole (40 mg) intended for the secondary prevention of heart attack and stroke. For patients who have suffered a heart attack or stroke, taking daily aspirin has been shown to help prevent the occurrence of a second …

  • AZRX: Non-systemic Focus on the GI Market Zacks Small Cap Research - Wed, Jan 25, 2017 10:00 AM EST

    The lead compound, MS 1819, is a yeast-derived lipase enzyme used to compensate for exocrine pancreatic insufficiency (EPI).  The compound has several superior characteristics compared to standard EPI therapy, demonstrating increased efficacy in low pH environments and derivation from a non-porcine source.  Currently MS …

  • Cell therapy is hot again! On December 12, 2016, Bayer AG and Versant Ventures joined forces to launch a new stem cell therapy company called BlueRock Therapeutics. BlueRock is focused on breakthrough treatments based on latest stem cell technology.

  • Two New Lawsuits: Finjan (FNJN) vs Avast/AVG and Cisco Zacks Small Cap Research - Mon, Jan 23, 2017 4:30 PM EST

    By Lisa Thompson, CFA NASDAQ:FNJN Finjan Sues Avast for AVG Products Finjan (NASDAQ:FNJN) filed suit on January 20, 2017 against Avast Software and AVG Technologies NV for more than $15.4 million in damages. ...

  • VRAY Readies For MRIdian-Linac Launch With $26M Raise Zacks Small Cap Research - Mon, Jan 23, 2017 4:00 PM EST

    By Anita Dushyanth, PhD NASDAQ:VRAY In order to help support its operations in 2017, ViewRay (NASDAQ:VRAY) announced (on January 18, 2017) that it had obtained gross proceeds of approximately $26 million ...

  • Zacks Update on Elio Motors – Misinformation Clarified Zacks Small Cap Research - Mon, Jan 23, 2017 11:15 AM EST

    Elio Motors (ELIO) is in the process of designing, developing and soon-to-be manufacturing an ultra-efficient, low-cost, three-wheeled, two-person vehicle.  With attractive performance, safety, fuel economy and aerodynamic styling characteristics, the Elio has the potential to become a game-changer leading to broad market …

  • Zacks SCR Initiates Coverage of IEG Holdings (IEGH) Zacks Small Cap Research - Mon, Jan 23, 2017 11:00 AM EST

    IEG Holdings Corp. (IEGH) is a consumer finance company that offers unsecured consumer loans (under the brand name “Mr. Amazing Loans”) to individuals in 19 states via an online platform (mramazingloans.com). The company provides $5,000 and $10,000 personal consumer loans over a term of five years in Alabama, Arizona, …

  • On January 12, 2017, BiondVax Pharmaceuticals Ltd. (BVXV) announced the publication of an article in the journal Vaccine titled “Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain” (Lowell et al., 2017). In the …

Next >>